LinkedIn Profile

Access Xellia Pharmaceuticals historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
private:xellia 1181570 Apr 14th, 2024 12:00AM Xellia Pharmaceuticals 49K 1293 Open Apr 14th, 2024 06:17AM Apr 14th, 2024 06:17AM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 13th, 2024 12:00AM Xellia Pharmaceuticals 49K 1295 Open Apr 13th, 2024 05:11AM Apr 13th, 2024 05:12PM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 12th, 2024 12:00AM Xellia Pharmaceuticals 49K 1295 Open Apr 12th, 2024 05:24AM Apr 12th, 2024 02:19PM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 11th, 2024 12:00AM Xellia Pharmaceuticals 49K 1295 Open Apr 11th, 2024 07:25AM Apr 11th, 2024 05:05PM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 10th, 2024 12:00AM Xellia Pharmaceuticals 49K 1294 Open Apr 10th, 2024 05:11AM Apr 11th, 2024 12:15AM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 9th, 2024 12:00AM Xellia Pharmaceuticals 49K 1295 Open Apr 9th, 2024 05:35AM Apr 9th, 2024 03:44PM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 8th, 2024 12:00AM Xellia Pharmaceuticals 49K 1295 Open Apr 8th, 2024 06:07AM Apr 8th, 2024 06:07AM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 7th, 2024 12:00AM Xellia Pharmaceuticals 49K 1294 Open Apr 7th, 2024 05:42AM Apr 7th, 2024 09:12PM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 7th, 2024 12:00AM Xellia Pharmaceuticals 49K 1297 Open Apr 7th, 2024 05:42AM Apr 7th, 2024 05:42AM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals
private:xellia 1181570 Apr 6th, 2024 12:00AM Xellia Pharmaceuticals 49K 1297 Open Apr 6th, 2024 05:23AM Apr 6th, 2024 05:23AM Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Open Active Pharmaceutical Ingredients, Contract Manufacturing, Finished Dosage Forms, Injectables, Anti-infectives, and Critical care Open Dalslandsgade 11 Copenhagen DK 2300 Xellia Pharmaceuticals

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.